Aytu BioPharma delivered its Form 8-K Current report EX-99.1 to the U.S. Securities and Exchange Commission on November 15, 2021.The company reported their financial results for its fiscal quarter 2022 ended September 30, 2021.Josh Disbrow, chief executive officer of Aytu BioPharma comments “We posted a very strong quarter with net revenues of $21.9 million and…
This content is viewable by members only. Visit MY ACCOUNT on the top menu to log in or to register for a 30 day free trial or purchase a subscription for UV Reporter 1 Year Single Membership or UV Reporter 1 Year Group Membership - $189 for first member and $25 for each additional member.
